Document is current
Any future updates will be listed below
-
Authors
Xing, Lijie
Lin, Liang
Yu, Tengteng
Li, Yuyin
Cho, Shih-Feng
Liu, Jiye
Wen, Kenneth
Hsieh, Phillip A.
Kinneer, Krista
Munshi, Nikhil
Anderson, Kenneth C.
Tai, Yu-Tzu
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (P50 CA100707, P01CA155258, RO1 CA 207237, P50 CA100707, P01CA155258, RO1 CA 207237)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
- License Information
-
More Information
Article History
Received: 3 November 2019
Revised: 14 January 2020
Accepted: 5 February 2020
First Online: 14 February 2020
Compliance with ethical standards
:
: KK is an employee of AstraZeneca and has stock and/or stock interests in AstraZeneca. NM serves on advisory boards to Millennium-Takeda, Celgene, and Novartis. KCA serves on advisory boards Celgene, Millennium-Takeda, Bristol-Myers Squibb, Gilead Sciences, Janssen, and Sanofi-Aventis and is a Scientific founder of OncoPep and C4 Therapeutics. All other authors declare no competing financial interests.
